Roberto Pazo-Cid
Verizon (United States)(US)Universidad de Zaragoza(ES)Hospital Universitario Miguel Servet(ES)Hospital Clínico Universitario Lozano Blesa(ES)Instituto de Investigación Sanitaria Aragón(ES)Instituto Aragonés de Ciencias de la Salud(ES)
Publications by Year
Research Areas
Pancreatic and Hepatic Oncology Research, Cancer Genomics and Diagnostics, Gastric Cancer Management and Outcomes, Cancer Immunotherapy and Biomarkers, Esophageal Cancer Research and Treatment
Most-Cited Works
- → First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial(2021)2,783 cited
- → Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial(2023)642 cited
- → Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis(2016)502 cited
- → Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer(2022)425 cited
- → NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial(2023)396 cited